trial

Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients

NCTId NCT00581243
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Terminated
Enrollment 32 (actual)
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer
Primary completion 2008-05-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Terminated
Enrollment
32 (actual)
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Triple
Start
2008-01-01
Primary completion
2008-05-01
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
SLV-313 SR

Sponsors

Wyeth is now a wholly owned subsidiary of PfizerLead Sponsor
Solvay PharmaceuticalsCollaborator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
32
Phase
PHASE1
Primary Completion Date
2008-05-01
Status
TERMINATED
relationships
The graph out of here
drug
SLV-313 SR
drug
lead_sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
company
collaborator
Solvay Pharmaceuticals
company
indication
Healthy
indication
Schizophrenia
indication